$345.18
0.65% yesterday
Nasdaq, Nov 25, 10:01 pm CET
ISIN
US5588681057
Symbol
MDGL
Sector
Industry

Madrigal Pharmaceuticals, Inc. Stock price

$345.18
+134.51 63.85% 1M
+115.60 50.35% 6M
+113.80 49.18% YTD
+147.88 74.95% 1Y
+260.04 305.43% 3Y
+238.65 224.02% 5Y
+236.68 218.14% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
-2.27 0.65%
ISIN
US5588681057
Symbol
MDGL
Sector
Industry

Key metrics

Market capitalization $7.53b
Enterprise Value $6.64b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 86.50
P/S ratio (TTM) P/S ratio 98.01
P/B ratio (TTM) P/B ratio 9.69
Revenue (TTM) Revenue $76.81m
EBIT (operating result TTM) EBIT $-548.05m
Free Cash Flow (TTM) Free Cash Flow $-433.32m
Cash position $1.00b
EPS (TTM) EPS $-25.07
P/E forward negative
P/S forward 47.42
EV/Sales forward 41.85
Short interest 29.83%
Show more

Is Madrigal Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Madrigal Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Madrigal Pharmaceuticals, Inc. forecast:

13x Buy
76%
3x Hold
18%
1x Sell
6%

Analyst Opinions

17 Analysts have issued a Madrigal Pharmaceuticals, Inc. forecast:

Buy
76%
Hold
18%
Sell
6%

Financial data from Madrigal Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
77 77
-
100%
- Direct Costs 3.66 3.66
618% 618%
5%
73 73
14,443% 14,443%
95%
- Selling and Administrative Expenses 339 339
349% 349%
442%
- Research and Development Expense 281 281
3% 3%
366%
-547 -547
57% 57%
-712%
- Depreciation and Amortization 0.88 0.88
73% 73%
1%
EBIT (Operating Income) EBIT -548 -548
57% 57%
-714%
Net Profit -519 -519
49% 49%
-675%

In millions USD.

Don't miss a Thing! We will send you all news about Madrigal Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Madrigal Pharmaceuticals, Inc. Stock News

Positive
The Motley Fool
3 days ago
When a company's shares shoot up 82% in 12 months, investors clearly think it's a good time to be a shareholder -- and that's exactly what's happened to the stock of Madrigal Pharmaceuticals (MDGL 5.53%). Earlier this year, the up-and-coming biotech received approval of a pioneering liver-disease treatment.
Positive
The Motley Fool
16 days ago
There's a bright future ahead for this company.
Neutral
GlobeNewsWire
20 days ago
CONSHOHOCKEN, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in fireside chats at three upcoming investor conferences:
More Madrigal Pharmaceuticals, Inc. News

Company Profile

Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.

Head office United States
CEO William Sibold
Employees 376
Founded 2011
Website www.madrigalpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today